CK20 is routinely used in combination with CK7 in distinguishing colon carcinomas (CK20+) from ovarian, pulmonary and breast carcinoma [ 30].
For this reason, biologics including etanercept are not routinely used in combination with drugs such as cyclosporine.
Bevacizumab is routinely used in combination with chemotherapy (e.g., irinotecan) for the treatment of recurrent glioblastoma [ 19, 142, 147].
It is routinely used in combination with 6MP in patients with ALL as it has been shown to reduce de novo purine synthesis and thus enhance the cytotoxicity of 6MP by promoting its conversion to 6TGNs [ 11, 12].
Levodopa is routinely administered in combination with a decarboxylase inhibitor, many of which are available as co-formulations under a variety of brand names in the US and Europe.
HIV-1 plasma viral load assays are routinely used in combination with CD4 T-cell counts in order to determine when to initiate therapy and when a treatment regimen is failing.
Growth on nitrate is linked to a rise in pH ϕ N O 3 − < 0, a net uptake of protons and is routinely used in combination with elevated CO2 to suppress pH changes through buffering associated with bicarbonate equilibrium.
In breast cancer, the ErbB2 specific antibody trastuzumab is now routinely given in combination with chemotherapy to ErbB2/HER2-positive breast cancer patients and has had a significant impact on patient mortality (Gianni et al, 2011).
